Preclinical studies that compared SYD985 with T-DM1 demonstrated encouraging activity of SYD985 in HER2-positive and HER2 low expression models, prompting exploration of SYD985 in a phase I trial in breast cancer and other HER2-expressing histologies[39]. This evidence concerns the gene ERBB2 and breast carcinoma.